Spectrum of biopsy-proven kidney diseases in 3514 patients at a single center in Northwest China from 2014 to 2023
摘要
The manifestations of renal diseases that precede CKD vary among populations and have changed over time. We investigated biopsy-proven renal diseases in patients from Northwest China over a 10-year period.
MethodsWe retrospectively analyzed data from 3514 renal biopsies performed at our center from January 2014 to December 2023 and compared the presentations (indications for biopsy) and clinicopathological diagnoses during two periods: 2014–2018 vs. 2019–2023.
ResultsOverall, primary glomerulonephritis (PGN) was the most common pathology (72.23%), followed by secondary glomerulonephritis (SGN, 21.35%), and tubulointerstitial diseases (2.79%). Membranous nephropathy (MN, 26.60%) and IgA nephropathy (IgAN, 24.02%) were the main diagnoses in patients with PGN. The proportion of PGN patients with MN and IgAN was greater during the latter period, but the proportion of those with focal segmental glomerular sclerosis was greater during the earlier period (all P < 0.05). Among SGN patients during the later period, the proportion of those with lupus nephritis (LN) and Henoch-Schönlein purpura nephritis (HSPN) was lower and proportion of those with diabetic nephropathy (DN) was greater (all P < 0.05).
ConclusionThis descriptive study in Northwest China showed that NS was the main indication for renal biopsy, PGN was the most common diagnosis, and MN was the predominant type of PGN. The proportions of MN and DN were greater in 2019–2023 than in 2014–2018, but the proportions of LN and HSPN had the opposite pattern. These results provide a foundation for future studies that seek to prevent CKD and improve patient outcomes.